The global human milk oligosaccharides market size is expected to reach USD 688.5 million by 2030, expanding at a CAGR of 14.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The global market for human milk oligosaccharides (HMOs) is being driven by several key factors. Firstly, there is a growing awareness among consumers about the health benefits of HMOs. Human milk is known to contain a complex mixture of bioactive compounds, and HMOs are one of the most abundant components. HMOs play a crucial role in supporting the development of a healthy immune system, promoting the growth of beneficial gut bacteria, and reducing the risk of certain diseases.
Secondly, there is an increasing demand for HMOs in the infant formula industry. As breastfeeding rates decline and more infants are fed with formula, manufacturers are seeking to bridge the nutritional gap between breast milk and formula. HMOs are being recognized as valuable additions to infant formula, as they can help mimic the benefits of human milk and provide a more complete nutritional profile for infants.
Furthermore, the market for HMOs is also being driven by advancements in biotechnology and production techniques. Traditionally, HMOs were extracted from human breast milk, which limited their availability and made them expensive. However, researchers have developed innovative methods to produce HMOs through microbial fermentation, making them more accessible and cost-effective. This has opened up new opportunities for HMO production and expanded their potential applications.
In May 2022, Nestlé China launched three new infant formulas containing human milk oligosaccharides (HMOs) for newborns with allergies to cow milk protein. The products are available via cross-border e-commerce as China does not allow HMOs in infant formula.
Request a free sample copy or view report summary: Human Milk Oligosaccharides Market Report
2’FL dominated the product type segment with a revenue share of over 36.9% in 2023 owing to the growing demand for infant formula that contains HMOs, particularly in regions where breastfeeding rates are low.
The infant formula was the dominant application in the global market, making up 75.6% of the total revenue in 2023. HMOs in infant formulas are in high demand for their benefits: gut health, memory enhancement, brain development, infection prevention, and prebiotic effects.
Some of the key players in the market include Chr. Hansen Holding A/S, Kyowa Hakko Europe GmbH, ZuChem Inc., Elicityl SA, FrieslandCampina Ingredients, Inbois N.V. and Carbosynth Limited.
Grand View Research has segmented the human milk oligosaccharides market on the basis of type, application, and region.
Human Milk Oligosaccharides Type Outlook (Revenue, USD Million; Volume, Metric Tons; 2018 - 2030)
2'FL
3'FL
3'SL
6'SL
LNT
LNnT
Human Milk Oligosaccharides Application Outlook (Revenue, USD Million; Volume, Metric Tons; 2018 - 2030)
Food & Beverages
Dietary Supplements
Infant Formula
Pharmaceuticals
Human Milk Oligosaccharides Regional Outlook (Revenue, USD Million; Volume, Metric Tons; 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
U.K.
Germany
France
Italy
Spain
Asia Pacific
China
Japan
India
Australia
Central & South America
Brazil
Middle East & Africa
South Africa
List of Key Players in the Human Milk Oligosaccharides Market
Chr. Hansen Holding A/S
Kyowa Hakko Europe GmbH
ZuChem Inc.
Elicityl SA
FrieslandCampina Ingredients
Inboise N.V.
Glycom A/S
DSM
Dextra Laboratories Limited
Carbosynth Limited
RAJVI ENTERPRISE
"The quality of research they have done for us has been excellent..."